Inductive has launched Beacon-2, a system that predicts the efficacious human dose of a small molecule directly from its chemical structure. The tool enables chemists to estimate which compounds will have the best human dose before laboratory synthesis. Beacon-2 predicts absorption, distribution, metabolism, excretion, and toxicity properties, then combines them through mechanistic pharmacokinetic models. Its underlying ADMET models have won three consecutive OpenADMET blind challenges, beating more than 750 competitors from leading AI and pharmaceutical companies. In testing, Inductive's medicinal chemistry agent used Beacon-2 to improve predicted human dose by 17 times over five autonomous design cycles on a SARS-CoV-2 compound. The system is available to partners through Compass and is already running on live drug discovery programmes. Inductive's models support over 100 discovery programmes with leading biopharma partners.

Inductive launches Beacon-2, making human dose computable for chemists and AI agents across biopharma. Business · SEP 17, 2026 PR Newswire Chemists can now estimate which compounds will have the best human dose before making them in the lab NEW YORK, Sept. 17, 2026 /PRNewswire/ - Inductive l... Chemists can now estimate which compounds will have the best human dose before making them in the lab NEW YORK, Sept. 17, 2026 /PRNewswire/ - Inductive launched Beacon-2 today, a system that predicts the efficacious human dose of a small molecule directly from its chemical structure. Dose is the number that decides whether a compound can become a drug. It accounts for both how potent a molecule is and what the body does to it. A drug that works at a lower dose also carries less risk of off-target toxicity. Beacon-2 predicts the properties that determine dose (absorption, distribution, metabolism, excretion, and toxicity) and estimates potency, then combines them through mechanistic models of pharmacokinetics. The ADMET models underneath it have won three consecutive OpenADMET blind challenges, beating more than 750 competitors from leading AI and pharma companies. A technical post published today covers how Beacon-2 works and how its projections across 20 real-world drug programs and 325 publicly available compounds from the ExpansionRx OpenADMET competition. To test how Beacon-2 impacts agentic design workflows, Inductive gave its medicinal chemistry agent Indy a recently disclosed SARS-CoV-2 compound for optimization. Over 5 autonomous design cycles, Indy improved predicted human dose by 17x, which can be the difference between a drug program that gets killed and one that makes it to clinical trials. "Chemists have always had to balance a dozen separate properties against each other to decide whether a compound is worth making," said Josh Haimson, co-founder and CEO of Inductive. "Dose is what those properties all add up to. Computing it from structure changes which compounds a team decides to make and helps them identify the highest quality compounds faster." Beacon-2 is available to partners through Compass, where it is already running on live drug discovery programs. About Inductive Inductive is a chemical intelligence organization that embeds into drug programs and deploys frontier AI across experiment design and physical execution. Their chemical intelligence models, lab robotics, and expert chemists reason together about which experiments are scientifically valuable and which can be executed in the physical world, improving with every experiment. Inductive's models have placed first in three consecutive blind AI drug discovery benchmarks and support over 100 discovery programs with leading biopharma partners. For more information, please visit www.inductive.bio SOURCE Inductive Bio, Inc. Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.